HK1044933B - 支鏈氨基酸依賴性氨基轉移酶的抑制劑及其在治療糖尿病性視網膜病中的應用 - Google Patents

支鏈氨基酸依賴性氨基轉移酶的抑制劑及其在治療糖尿病性視網膜病中的應用

Info

Publication number
HK1044933B
HK1044933B HK02106385.8A HK02106385A HK1044933B HK 1044933 B HK1044933 B HK 1044933B HK 02106385 A HK02106385 A HK 02106385A HK 1044933 B HK1044933 B HK 1044933B
Authority
HK
Hong Kong
Prior art keywords
aminotranserase
inhibitors
dependent
treatment
amino acid
Prior art date
Application number
HK02106385.8A
Other languages
English (en)
Other versions
HK1044933A1 (en
Inventor
J‧S‧布賴恩斯
L-Y‧胡
S‧M‧赫特森
K‧F‧蘭歐
E‧列斯
M‧F‧拉弗蒂
T‧R‧賴德
T-Z‧蘇
D‧F‧威爾蒂
D‧J‧伍斯特羅
Original Assignee
沃尼爾‧朗伯公司
賓西法尼亞州研究基金會
威克福雷大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 沃尼爾‧朗伯公司, 賓西法尼亞州研究基金會, 威克福雷大學 filed Critical 沃尼爾‧朗伯公司
Publication of HK1044933A1 publication Critical patent/HK1044933A1/xx
Publication of HK1044933B publication Critical patent/HK1044933B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/11—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK02106385.8A 1999-12-08 2002-08-29 支鏈氨基酸依賴性氨基轉移酶的抑制劑及其在治療糖尿病性視網膜病中的應用 HK1044933B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16963599P 1999-12-08 1999-12-08
US17539900P 2000-01-11 2000-01-11
US23002000P 2000-09-05 2000-09-05
PCT/US2000/030769 WO2001042191A1 (en) 1999-12-08 2000-11-08 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of diabetic retinopathy

Publications (2)

Publication Number Publication Date
HK1044933A1 HK1044933A1 (en) 2002-11-08
HK1044933B true HK1044933B (zh) 2005-06-03

Family

ID=27389690

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02106385.8A HK1044933B (zh) 1999-12-08 2002-08-29 支鏈氨基酸依賴性氨基轉移酶的抑制劑及其在治療糖尿病性視網膜病中的應用

Country Status (33)

Country Link
EP (1) EP1157000B1 (zh)
JP (1) JP2003516379A (zh)
KR (1) KR20010101811A (zh)
CN (2) CN1626069A (zh)
AP (1) AP2001002242A0 (zh)
AR (1) AR037738A1 (zh)
AT (1) ATE308510T1 (zh)
AU (1) AU784553B2 (zh)
BG (1) BG105875A (zh)
BR (1) BR0008443A (zh)
CA (1) CA2361647A1 (zh)
CO (1) CO5280055A1 (zh)
CZ (1) CZ20012758A3 (zh)
DE (1) DE60023657T2 (zh)
DZ (1) DZ3141A1 (zh)
EA (1) EA006597B1 (zh)
EE (1) EE200100416A (zh)
ES (1) ES2252075T3 (zh)
GE (1) GEP20043298B (zh)
HK (1) HK1044933B (zh)
HR (1) HRP20010581A2 (zh)
HU (1) HUP0200570A3 (zh)
IS (1) IS6033A (zh)
MA (1) MA26777A1 (zh)
MX (1) MXPA01008085A (zh)
NO (1) NO20013844L (zh)
OA (1) OA11759A (zh)
PE (1) PE20010929A1 (zh)
PL (1) PL349193A1 (zh)
SK (1) SK11022001A3 (zh)
UY (1) UY26474A1 (zh)
WO (1) WO2001042191A1 (zh)
YU (1) YU57401A (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
AU2002310409C1 (en) * 2001-06-11 2008-04-17 Xenoport, Inc. Orally administered dosage forms of GABA analog prodrugs having reduced toxicity
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
MXPA02010231A (es) * 2001-11-27 2004-12-13 Warner Lambert Co Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas.
MXPA02010430A (es) * 2001-11-27 2003-06-02 Warner Lambert Co Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas.
US20040058313A1 (en) * 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
DE602004010135T2 (de) * 2004-09-20 2008-09-04 Kao Corp. Verfahren zur Herstellung von Lactonen und deren Verwendung als Geruchsstoffe
EP1811986B1 (en) 2004-11-04 2014-03-26 XenoPort, Inc. Gabapentin prodrug sustained release oral dosage forms
WO2008103319A2 (en) * 2007-02-16 2008-08-28 Ark Diagnostics, Inc. Compounds and methods for use in detecting gabapentin
WO2008155619A2 (en) * 2007-06-21 2008-12-24 Pfizer Inc. Preparation of optically-active cyclic amino acids
EP2383255A1 (en) 2010-04-28 2011-11-02 Lacer, S.A. New compounds, synthesis and use thereof in the treatment of pain
EP2481801A1 (en) 2011-01-28 2012-08-01 Deutsches Krebsforschungszentrum Inhibitors of branched-chain-aminotransferase-1 (BCAT1) for the treatment of neoplasia
US10941109B2 (en) 2011-06-13 2021-03-09 Ergon Pharmaceuticals Llc Compositions and methods of treatment using a BCAT1 inhibitor
JP6053768B2 (ja) * 2011-06-13 2016-12-27 エルゴン ファーマシューティカルズ エルエルシー Ｂｃａｔ１阻害剤を使用する治療方法
CN113694202B (zh) * 2020-06-29 2023-03-31 江苏省中医院 Ass1或bckdk抑制剂在制备治疗溃疡性结肠炎的药物中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2167717T3 (es) * 1996-03-14 2002-05-16 Warner Lambert Co Nuevos aminoacidos ciclicos sustituidos como agentes farmaceuticos.

Also Published As

Publication number Publication date
WO2001042191A1 (en) 2001-06-14
AU784553B2 (en) 2006-05-04
SK11022001A3 (sk) 2002-11-06
ES2252075T3 (es) 2006-05-16
CN1344245A (zh) 2002-04-10
DE60023657D1 (de) 2005-12-08
BR0008443A (pt) 2001-10-30
EE200100416A (et) 2002-12-16
UY26474A1 (es) 2001-01-31
ATE308510T1 (de) 2005-11-15
BG105875A (en) 2002-05-31
DZ3141A1 (fr) 2001-01-14
CA2361647A1 (en) 2001-06-14
CN1626069A (zh) 2005-06-15
CO5280055A1 (es) 2003-05-30
CZ20012758A3 (cs) 2002-09-11
JP2003516379A (ja) 2003-05-13
PL349193A1 (en) 2002-07-01
HUP0200570A3 (en) 2003-02-28
AR037738A1 (es) 2004-12-01
EA200100791A1 (ru) 2002-04-25
NO20013844D0 (no) 2001-08-07
EP1157000B1 (en) 2005-11-02
GEP20043298B (en) 2004-03-10
EA006597B1 (ru) 2006-02-24
CN1170811C (zh) 2004-10-13
DE60023657T2 (de) 2006-07-20
YU57401A (sh) 2004-05-12
MA26777A1 (fr) 2004-12-20
HUP0200570A2 (en) 2002-06-29
HK1044933A1 (en) 2002-11-08
MXPA01008085A (es) 2002-04-24
OA11759A (en) 2005-07-19
EP1157000A1 (en) 2001-11-28
PE20010929A1 (es) 2001-09-08
HRP20010581A2 (en) 2002-08-31
AU1477901A (en) 2001-06-18
AP2001002242A0 (en) 2001-09-30
IS6033A (is) 2001-07-31
KR20010101811A (ko) 2001-11-14
NO20013844L (no) 2001-10-04

Similar Documents

Publication Publication Date Title
HK1044933B (zh) 支鏈氨基酸依賴性氨基轉移酶的抑制劑及其在治療糖尿病性視網膜病中的應用
HUP0203367A3 (en) Benzylidine-thiazolidinediones and analogues and their use in the treatment of diabetes
IL187512A0 (en) Use of (s,s)-reboxetine in the treatment of pain conditions and incontinence
AU1166502A (en) Human ect2 and methods of use
IL144508A0 (en) Compositions and methods for use in targeting vascular destruction
AU2001293553A1 (en) Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment
HK1044545A1 (zh) 貝他分泌酶組合物及其方法
CY2006007I2 (el) Χρηση αναστολεων cgmp-φωσφοδιεστερασης στην αγωγη της ανικανοτητας
DE60019490D1 (de) Brennstofförder-und behandlungsvorrichtung
AU2002365311A1 (en) Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
AU8878801A (en) Agent and method of prevention and treatment of cancer in animals
AU5754701A (en) Method of using cox-2 inhibitors in the treatment and prevention of ocular cox-2mediated disorders
AP2002002393A0 (en) Naphthoquinone derivatives and their use in the treatment and control of tuberculosis
PL352333A1 (en) Dihydrobenzodiazepines and use of same in treatment of dislipidemia
HUP0105284A3 (en) Inhibitors for use in hemostasis and immune function
AU2002346594A1 (en) Use of hiv-1 protease inhibitors and their derivatives in the treatment of inflammation
AU7688998A (en) Use of metalloproteinase inhibitors in the treatment and prevention of pulmonaryemphysema
IL144644A0 (en) Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of diabetic retinopathy
HK1049329B (zh) 苯並噁-和苯並噻唑基氨基硫酸酯和其做為類固醇硫酸酯酶抑制劑的用途
EP1189584A4 (en) CARE AND DERMATOLOGICAL COMPOSITION BASED ON ALPHA-AMINO ACID
AU4923100A (en) Use of the combination of amino acids having an aliphatic side chain and having a basic side chain in topical hair treatment
EE200100363A (et) ((Aminoiminometüül)amino)alkaankarboksamiidid ja nende kasutamine ravis
GB9903919D0 (en) Aminophenols and their therapeutic use
GB9905300D0 (en) Therapy and use of agents in therapy
AU2860500A (en) Treatement of colic and gut spasm in horses and other vertebrates

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20081108